Merck & Company Inc (MRK) — closed signal from March 22, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 20, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published March 22, 2026
Merck looks attractive now because investors are favoring safer healthcare companies, the business generates steady cash, and the recent price drop put shares into a calmer area where buyers may step in. New positive data on GARDASIL 9 gives a timely reason for interest. A rebound seems possible over the next 0-3 months, though the recovery is not yet clearly established.
Primary drivers
- Healthcare seen as safer during market turbulence
- New GARDASIL 9 data strengthens the sales story
- Consistent profits help limit downside risk
- Recent weakness set up a clearer buying range
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.